top of page
Marita Zimmermann Headshot
  • LinkedIn Social Icon

Dr. Marita Zimmermann








Pre-marriage name: Marita Mann

I am a health economist, epidemiologist, and global health researcher, and am passionate about using high quality research methods to increase value in health.


I believe that health care is a human right, and we do not have unlimited resources for health. My goal is to use econometric, epidemiologic, and modeling methods to figure out how to get the most bang for our health care buck.


I aim to work on projects that have current usability or policy relevance, and can influence real change in healthcare for patients in real time.



What are your research questions and goals? Do you want to prioritize which interventions to fund? Inform a ministry of health about the long term impact of a new vaccine campaign? Demonstrate the value of a new product to payer or other stakeholder? I can help you define your research question and design a research or modeling approach to fit your needs, audience, and budget.



Have your research ready to go but have some methodological questions? Need some extra personnel to get the work done quickly and efficiently? I complete analyses and models with methodological rigor and timeliness. I work with you to meet timeline and budgetary restraints. I complete deliverables on time that meet your needs.


Health economics research has a wide variety of stakeholders and audiences, from policy makers, patients, and payers to academics and clinicians. I can help you identify and execute the best ways to get your message to your stakeholders. Frequent modes of communication are peer-reviewed manuscripts, interactive tools, or animated presentations.


Senior Research Economist


Affiliate Assistant Professor


I teach a course to graduate level student on health economic methodology, Economic Evaluation in Health and Medicine, in addition to mentoring students and engagement in the health economics and outcome research program, Comparative Health Outcomes, Policy & Economics (CHOICE) Institute.


Research Scientist


Institute for Clinical and Economic Review

I worked on the UW research team with the Comparative Health Outcomes, Policy & Economics (CHOICE) Institute to complete health economic research in collaboration with ICER. We complete cost-effectiveness models in various disease areas, including multiple sclerosis, atopic dermatitis, and blindness. We generate reports used to guide coverage decisions and other policies. We then present our work at national meetings for groups of payers, industry representative, patient advocates, physician groups, and other stakeholders. For the first year of the work I was a post-doctoral fellow, then transitioned to my current position.


Health Economist


I consult as a health economist both under my own consulting firm focusing on global health, Consultants in Global Health LLC, and under an experienced U.S. based consultancy, Veritech Corporation. Our clients are based around the world, and include pharmaceutical and biotechnology companies, as well as non-profit and other non-governmental organizations such as PATH and KidRisk. Projects include budget impact models, cost-effectiveness evaluations, costing studies, program evaluation, data analysis, and others.


Development Engineer


I worked as a chemical engineer and a liaison between research and manufacturing, observing all aspects of the pharmaceutical industry and path to distribution. I had responsibility for product from Phase IIb through post-market monitoring. Our group designed drug product manufacturing processes and transferred these processes to full-scale manufacturing sites worldwide. I assisted in writing FDA filings and organizing all necessary information and used Quality by Design and Lean Six Sigma principles to create first-rate products.



Seattle, WA

My work aims to expand the global health disease modeling work to increase applicability and usability by decision makers, such as incorporation of costs, logistical constraints, or health system limitations. Current work focuses on modeling women's empowerment and economic opportunity. We strive to be a link between finance and modeling researchers, implementing methodology to combine the needs and expertise of both sides with the overarching goal of increasing value for money in resource-limited settings. 




Comparative Health Outcomes, Policy, and Economics Program

Dissertation Topic: Feasibility and Cost-Effectiveness of a National Active Surveillance Pharmacovigilance System for HAART in Namibia

Awards: ARCS Scholar, Thomas Francis Jr. Fellowship Recipient, Reducing Barriers to the Ambitious Scholarship Recipient


Master of Public Health


Department of Epidemiology

Thesis Title: Unplanned Antiretroviral Treatment Interruptions Induced by the Kenyan Post-Election Crisis are Associated with HIV Virologic Failure

Awards: Global Health Scholarship, Framework Grant Recipient


Bachelor of Science


Carnegie Institute of Technology

Double Major: Chemical Engineering and Biomedical Engineering

Awards: University Honors, McCabe Society Recognition for Service to University and Community


Marita Zimmermann, Roy Burstein, Carrie Bennette, Dennis Chao, Mike Famulare, Niket Thakkar, Lauren George, Edward Wenger, Mandy Izzo, and Jen Schripsema. COVID-19 Epidemic Shifts Younger While Inequalities Grow Wider in Washington State.” June 25, 2020.


Niket Thakkar, Marita Zimmermann, Roy Burstein, Edward Wenger, and Mike Famulare. “Comparing COVID-19 Dynamics in King and Yakima Counties”. May 28, 2020.


Marita Zimmermann, Amy E Benefield, and Benjamin M Althouse. 2020. “They Stumble That Run Fast: The Economic and COVID-19 Transmission Impacts of Reopening Industries in the US.” MedRxiv, June, 2020.06.11.20128918.


Dennis Chao, Marita Zimmermann, on behalf of the IDM COVID-19 Response. “Mobility and Phased Re-Opening in Washington.” July 31, 2020.


Brittany Hagedorn, Marita Zimmermann, Cliff Kerr, Grace Huynh, and Jen Schripsema. “Model-Based Estimates of Time to Maximum Bed Occupancy for COVID-19 Care.” April 2, 2020.


Marita Zimmermann. “Comparison of Costs of School Closures versus COVID-19 Inpatient Treatment in Seattle.” March 19, 2020.

Peer Reviewed Publications

Japanese Encephalitis Vaccination in the Philippines: A Cost-Effectiveness Analysis Comparing Alternative Delivery Strategies.

Vodicka, Elisabeth, Marita Zimmermann, Anna Lena Lopez, Maria Wilda Silva, Leonita Gorgolon, Toda Kohei, Jessica Mooney, Farzana Muhib, Clint Pecenka, and Anthony A. Marfin.

Vaccine. 2020 38 (13): 2833–40. 

Projection of Costs of Polio Eradication Compared to Permanent Control.

Marita Zimmermann, Brittany Hagedorn, and Hil Lyons.

Journal of Infectious Diseases. 2020 221 (4): 561–65. 

Household Costs of Diarrhea by Etiology in 7 Countries, the Global Enterics Mulitcenter Study (GEMS).”

Zimmermann, M., K. Kotloff, D. Nasrin, A. Roose, M.M. Levine, R. Rheingans, T. Farag, D. Walker, and C. Pecenka. 

Open Forum Infectious Diseases. 2019 6 (4).

Cost Utility of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease.

Marita Zimmermann, Solomon J. Lubinga, Reiner Banken, David Rind, Geri Cramer, Patricia G. Synnott, Richard H. Chapman, Sonya Khan, and Josh Carlson

Value in Health. 2019 22 (2): 161–67.

Estimating the Costs of HIV Clinic Integrated versus Non-Integrated Treatment of Precancerous Cervical Lesions and Costs of Cervical Cancer Treatment in Kenya.

Vodicka, Elisabeth L., Michael H. Chung, Marita R. Zimmermann, Rose J. Kosgei, Fan Lee, Nelly R. Mugo, Timothy C. Okech, et al.

PLoS ONE. 2019 14 (6).

Optimization of Frequency and Targeting of Measles Supplemental Immunization Activities in Nigeria: A Cost-Effectiveness Analysis.

Marita Zimmermann, Kurt Frey, Brittany Hagedorn, A. J. Oteri, Abdulazeez Yahya, Maimuna Hamisu, Fred Mogekwu, Faisal Shuaib, Kevin A. McCarthy, and Guillaume Chabot-Couture

Vaccine. 2019 37 (41): 6039–47.

Assessment tool for establishing local pharmaceutical manufacturing in low- and middle-income countries.

Zimmermann M, Adamson B, Lam-Hine T, Rennie T, Stergachis, A.

Int J Pharm Prac. 2018 Aug;26(4)364-368.

Heart rate variability testing: could it change spending for rheumatoid arthritis patients in the United States? An exploratory economic analysis.

Zimmermann M, Vodicka E, Holman AJ, Garrison LP.

Journal of Medical Economics. 2018 Jul;21(7)712–720.

Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis.

Zimmermann M, Rind D, Chapman R, Kumar V, Kahn S, Carlson J.

Journal of Drugs in Dermatology. 2018 Jul;17(7)750–756.

Cost-effectiveness analysis of the orbital atherectomy system: Two-year follow-up.

Garrison L, Zimmermann M, Young C, Crittendon J, Généreux P.

Cardiovascular Revascularization Medicine. 2017 Mar;18(2)86–90.

Zimmermann M, Vodicka E, Babigumira JB, Okech T, Mugo N, Sakr S, Garrison LP, Chung MH. Cost-effectiveness of cervical cancer screening and preventative cryotherapy at an HIV treatment clinic in Kenya. Cost Ef Resour Alloc. 2017 Dec;15(1)13.

Insights from a Systematic Search for Information on Designs, Costs, and Effectiveness of Poliovirus Environmental Surveillance Systems.

Duintjer Tebbens, R.J., Zimmermann, M., Pallansch, M.A., Thompson, K.

Food Environ Virol (2017). doi:10.1007/s12560-017-9314-4


Misclassification of Antiretroviral Treatment Failure Using WHO 2006 and 2010/2013 Immunologic Criteria in HIV-Infected Children and Adolescents in Western Kenya.

Dufort EM, DeLong AK, Mann M, Nyandiko WM, Ayaya SO, Hogan JW, Kantor R.

Infectious Diseases Society. 2017 Sept;6(3)285-288.

Costs of integrating cervical cancer screening at an HIV clinic in Kenya.

Vodicka EL, Babigumira JB, Mann MR, Kosgei RJ, Lee F, Mugo NR, Okech TC, Sakr SR, Garrison LP Jr, Chung MH.

Int J Gynaecol Obstet. 2017 Feb;136(2):220-228.


Active Surveillance versus Spontaneous Reporting for First-Line Antiretroviral Medicines in Namibia: A Cost-Utility Analysis.

Mann M, Mengistu A, Gaeseb J, Sagwa E, Mazibuko G, Babigumira JB, Garrison LP Jr, Stergachis A.

Drug Saf. 2016 Sep;39(9):859-72. 

Sentinel site active surveillance of safety of first-line antiretroviral medicines in Namibia.
Mann M, Mengistu A, Gaeseb J, Sagwa E, Mazibuko G, Baeten JM, Babigumira JB, Garrison LP, Stergachis A.
Pharmacoepidemiol Drug Saf. 2016 Sep;25(9):1052-60.

The potential cost-effectiveness of the Diamondback 360® Coronary Orbital Atherectomy System for treating de novo, severely calcified coronary lesions: an economic modeling approach.
Chambers J, Généreux P, Lee A, Lewin J, Young C, Crittendon J, Mann M, Garrison LP.
Ther Adv Cardiovasc Dis. 2016 Apr;10(2):74-85. 

Misclassification of Antiretroviral Treatment Failure Using WHO 2006 and 2010/2013 Immunologic Criteria in HIV-Infected Children and Adolescents in Western Kenya.
Dufort EM, DeLong AK, Mann M, Nyandiko WM, Ayaya SO, Hogan JW, Kantor R.
J Pediatric Infect Dis Soc. 2016 Apr 29. 


The clinical and cost burden of coronary calcification in a Medicare cohort: An economic model to address under-reporting and misclassification.
Garrison LP Jr, Lewin J, Young CH, Généreux P, Crittendon J, Mann MR, Brindis RG.
Cardiovasc Revasc Med. 2015 Oct-Nov;16(7):406-12.

HIV-1 RNA levels and antiretroviral drug resistance in blood and non-blood compartments from HIV-1-infected men and women enrolled in AIDS clinical trials group study A5077.
Kantor R, Bettendorf D, Bosch RJ, Mann M, Katzenstein D, Cu-Uvin S, D'Aquila R, Frenkel L, Fiscus S, Coombs R; ACTG A5077 Study Team.
PLoS One. 2014 Apr 3;9(4):e93537. 

Antiretroviral treatment interruptions induced by the Kenyan postelection crisis are associated with virological failure.
Mann M, Diero L, Kemboi E, Mambo F, Rono M, Injera W, Delong A, Schreier L, Wools-Kaloustian K, Sidle J, Buziba N, Kantor R.
J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):220-4.


Capacity building and predictors of success for HIV-1 drug resistance testing in the Asia-Pacific region and Africa.Land S, Zhou J, Cunningham P, Sohn AH, Singtoroj T, Katzenstein D, Mann M, Sayer D, Kantor R.

J Int AIDS Soc. 2013 Jul 10;16:18580.

How does use of a prescription monitoring program change pharmacy practice?
Green TC, Mann MR, Bowman SE, Zaller N, Soto X, Gadea J, Cordy C, Kelly P, Friedmann PD.
J Am Pharm Assoc (2003). 2013 May-Jun;53(3):273-81.


Effects of political conflict-induced treatment interruptions on HIV drug resistance.

Mann M, Lurie MN, Kimaiyo S, Kantor R.

AIDS Rev. 2013 Jan-Mar;15(1):15-24. 

How does use of a prescription monitoring program change medical practice?
Green TC, Mann MR, Bowman SE, Zaller N, Soto X, Gadea J, Cordy C, Kelly P, Friedmann PD.
Pain Med. 2012 Oct;13(10):1314-23.

Life after the ban: an assessment of US syringe exchange programs' attitudes about and early experiences with federal funding.
Green TC, Martin EG, Bowman SE, Mann MR, Beletsky L.
Am J Public Health. 2012 May;102(5):e9-16.



Microsoft Excel - Visual Basic

Statistical Analysis:

R, Stata, SAS

Cost-Effectiveness Models

Burden of Illness Analysis

Peer-Reviewed Publications

Global Health Research

Budget Impact Models

Health Insurance Claims Data Analysis


Cost-Finding Studies

Communicating Results to Stakeholders

Implementation Science

bottom of page